Next 10 |
Sigyn Therapeutics (OTCQB: SIGY) , a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current...
Sigyn Therapeutics (OTCQB: SIGY) , a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer the...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoP...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeu...
Sigyn Therapeutics is developing four medical device candidates – Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) – designed to overcome current therapeutic limitations in healthcare Sigyn Therapy(TM), the company’s lead product candidate, is a single-us...
Sigyn’s common stock, temporarily trading under the ticker symbol “SIGYD”, is set to revert back to its historic symbol “SIGY” on February 29, 2024. The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that targe...
Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy ...
SAN DIEGO, CA - ( NewMediaWire ) - February 21, 2024 - Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology company, announced today the filing ...
SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology company, announced today...
Sigyn Therapeutics (OTCQB: SIGY, SIGYD) , a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company ...
News, Short Squeeze, Breakout and More Instantly...
Sigyn Therapeutics Inc Company Name:
SIGY Stock Symbol:
OTCMKTS Market:
Sigyn Therapeutics (OTCQB: SIGY) , a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current...
Sigyn Therapeutics (OTCQB: SIGY) , a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer the...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoP...